biostudies-literatureUnknown190(12)Windle SB<h4>Background</h4>Patients who continue to smoke after acute coronary syndrome are at increased risk of reinfarction and death. We previously found use of varenicline to increase abstinence 24 weeks after acute coronary syndrome; here we report results through 52 weeks.<h4>Methods</h4>The EVITA trial was a multicentre, double-blind, randomized, placebo-controlled trial of varenicline for smoking cessation in patients admitted to hospital with acute coronary syndrome. Participants were randomly assigned (1:1) to receive varenicline or placebo for 12 weeks, in conjunction with low-intensity counselling. Smoking abstinence was assessed via 7-day recall, with biochemical validation using exhaled carbon monoxide. Participants lost to follow-up or withdrawn were assumed to have returned to smokCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienneE347-E354https://www.ebi.ac.uk/biostudies/studies/S-EPMC5871438biostudies-literatureSmoking abstinence 1 year after acute coronary syndrome: follow-up from a randomized controlled trial of varenicline in patients admitted to hospital.PMC5871438Windle SBDehghani PCassavar DLambert CEVITA InvestigatorsGrondin FRIskander AHaught HDion DBaril JFEisenberg MJLauzon COld WMehta SRAbramson BLBata IClarke ARoy NSrivastava NMadan MfalseSmoking abstinence 1 year after acute coronary syndrome: follow-up from a randomized controlled trial of varenicline in patients admitted to hospital.<h4>Background</h4>Patients who continue to smoke after acute coronary syndrome are at increased risk of reinfarction and death. We previously found use of varenicline to increase abstinence 24 weeks after acute coronary syndrome; here we report results through 52 weeks.<h4>Methods</h4>The EVITA trial was a multicentre, double-blind, randomized, placebo-controlled trial of varenicline for smoking cessation in patients admitted to hospital with acute coronary syndrome. Participants were randomly assigned (1:1) to receive varenicline or placebo for 12 weeks, in conjunction with low-intensity counselling. Smoking abstinence was assessed via 7-day recall, with biochemical validation using exhaled carbon monoxide. Participants lost to follow-up or withdrawn were assumed to have returned to smok2018-01-01T00:00:00Z2018 Mar2025-05-31T22:56:41.211Z2019-06-06T19:14:02ZS-EPMC58714382958116110.1503/cmaj.170377